3635 results for «326»

Filter By

3635 results

Most impactful trials in structural heart disease 2024/2025

30 Sep 2025 – From PCR Gulf Valves 2025

Delve into the most impactful structural heart disease trials shaping 2024 and 2025. This session addresses current dilemmas in TAVI, including early intervention and management of small annuli, evaluates evidence for transcatheter mitral and tricuspid valve repair, and identifies evidence gaps relevant to the region, providing...

Most impactful trials in structural heart disease 2024/2025

Expanding horizons with balloon-expandable TAVI - LIVE Case

12 Sep 2025 – From PCR Rio Valves 2025

A 76-year-old male with a history of abdominal and iliac stent grafts (2022), severe COPD, prostate cancer, and gastric ulcer presented with symptomatic severe aortic stenosis. CT and echocardiography showed a calcified bicuspid aortic valve with preserved LV function.

A 24.5 mm Myval valve was implanted without...

Expanding horizons with balloon-expandable TAVI - LIVE Case

Stent failure - LIVE Case

11 Oct 2025 – From AICT-AsiaPCR 2025

This educational session presents a live case from Apollo Hospitals, Chennai, focusing on stent failure management. It emphasizes the critical role of imaging in optimizing treatment for in-stent restenosis, discusses essential lesion preparation tools, and reviews various therapeutic options to improve patient care.

 LIVE Educational Case from...

Stent failure - LIVE

MedAlliance SELUTION SLR is the first DEB to receive coronary de novo IDE Aapproval , its Fourth FDA IDE DEB approval

10 Jan 2023

Over 1,000 patients enrolled in landmark SELUTION DeNovo study

14 Mar 2023

MedAlliance leads US Sirolimus DEB race: first US patient enrolled into SELUTION SLR coronary sirolimus DEB study

25 Jan 2023

MedAlliance to be acquired by Cordis

18 Oct 2022

POPular TAVI - Antithrombotic Therapy After Transcatheter Aortic Valve Implantation in Patients With a Long-Term Indication for Oral Anticoagulation

04 Apr 2020

The POPular TAVI trial is an open label randomized study designed to evaluate oral anticoagulation (OAC) alone compared with OAC plus clopidogrel for 3 months in patients undergoing transcatheter aortic valve replacement (TAVR) with a long-term indication for oral anticoagulation. Those who had undergone percutaneous revascularization...

Dr. Mirvat Alasnag

Author

Mirvat Alasnag
Primary endpoint of All Bleeding

MedAlliance SELUTION SLR Receives Coronary FDA IDE Approval

24 Oct 2022

MedAlliance announces enrollment of over 1,660 patients in landmark SELUTION DeNovo study

14 Sep 2023

MedAlliance acquired by Cordis for up to USD 1.135 billion

02 Oct 2023

Why hypertension is a major unresolved problem

02 Oct 2024

Explore the global challenge of hypertension, affecting one in three adults, and the strategies for screening, diagnosis, and management, including lifestyle modifications, pharmacotherapy, and device-based treatments, as outlined by Sofie Brouwers.

Sofie Brouwers

Author

Sofie Brouwers
Why hypertension is a major unresolved problem

Biocardia receives FDA breakthrough device designation for CardiAMP Cell Therapy System for heart failure

03 Feb 2022

RENOVATE-COMPLEX-PCI: Intravascular imaging-guided versus angiography-guided procedural optimization in complex percutaneous coronary intervention

06 Mar 2023

Daniele Giacoppo reports the main results of the RENOVATE-COMPLEX-PCI trial presented by Joo-Yong Hahn, from the Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, in a Late-Breaking Trial session at the American College of Cardiology (ACC) 2023 / World...

Daniele Giacoppo

Author

Daniele Giacoppo
RENOVATE-COMPLEX-PCI: Intravascular imaging-guided versus angiography-guided procedural optimization in complex percutaneous coronary intervention

Surgical left atrial appendage occlusion in VHD without AF: OPINION Trial

03 Sep 2025

Alex Sticchi provides his take on the results of the OPINION trial presented by Yang Wang at the ESC Congress 2025 in Madrid.

Alessandro Sticchi

Author

Alessandro Sticchi
OPINION Trial: 1-year outcomes
Didn’t find what you were looking for?